November 14, 2017 - report from Los Angeles, CA, USA and Oslo, Norway – World Diabetes Day is the world’s largest diabetes awareness campaign. This year’s theme, Women and Diabetes, promotes the importance of access for all women with diabetes to education, treatment and care.
Oslo Red Cross Conference Centre - educational talks and DR screening for ethnic minority women
PR-Inside.com: 2017-11-14 11:33:36
Preventing the preventable: Combating diabetic retinopathy in at risk women
November 14, 2017 - report from Los Angeles, CA, USA and Oslo, Norway – World Diabetes Day is the world’s largest diabetes awareness campaign. This year’s theme, Women and Diabetes, promotes the importance of access for all women with diabetes to education, treatment and care. Oslo University Hospital/University of Oslo in collaboration with Eyenuk Inc. recently highlighted the importance of early detection of diabetic retinopathy (DR) in women in a live screening of ethnic minority women in Oslo, Norway.
On November 1st at the Oslo Red Cross Conference Centre, Oslo Red Cross along with the Norwegian Women's Public Health Association, and The Norwegian Diabetes Association organized educational talks and DR screening for ethnic minority women took place. With support provided by ophthalmologists from the Oslo University Hospital/University of Oslo, over 150 women attended the event which was titled Could I have diabetes? A health day for women. A series of three presentations focused on diabetes, DR and the impact of food and nutrition on health.
During the subsequent DR screening, EyeArt™, a machine learning, cloud-based, medical software screening tool developed by Eyenuk Inc., was used to rapidly grade fundus images automatically in parallel to ophthalmologists grading the same images. EyeArt can automatically detect diabetic eye disease by analyzing the presence, sizes, positions and number of lesions within the eye. The results showed 100% agreement with expert diagnosis on all patients with sight threatening retinopathy (STR).
Explaining the importance of the event, Dr. Goran Petrovski, Professor at the Department of Ophthalmology and Head of the Center for Eye Research, Oslo University Hospital/University of Oslo, Norway, stated “The prevalence of diabetes in ethnic minorities is 3-4 times higher than that of the native Norwegian population.” He added also that “Automated screening provides an efficient and accurate way of detecting DR, and through the event, we were able to get first-hand, real world experience with a tool like EyeArt™.”
Based in California, Eyenuk is passionate about radically reducing preventable blindness in working age population. EyeArt™ is the company’s first CE marked solution, and can automatically analyze multiple retinal images captured by fundus cameras during diabetic patient visits. As a result, the screening tool provides a recommendation at the point-of-care for the individual to see an eye specialist based on its automated detection and analysis.
“We are excited to have been involved in the live DR screening in Oslo,” said Eyenuk CEO, Dr. Kaushal Solanki. “EyeArt has been clinically validated using more than one million retinal fundus images and is gaining recognition as a DR screening tool,“ added Dr. Solanki.
For more information or a free EyeArt trial version (Europe only) contact Eyenuk at email@example.com
About Oslo University Hospital
Oslo University Hospital is a highly specialised hospital in charge of extensive regional and local hospital assignments and the provision of high quality services for the citizens of Oslo and the South-East Health Region of Norway in all specialties including ophthalmology. The hospital also has a nationwide responsibility for a number of national and multi-regional assignments and has several national centres of competence.
About University of Oslo (UiO)
The University of Oslo is a leading European university and Norway's largest. UiO is home to outstanding research and offers a great variety of studies.
Eyenuk, Inc., is focused on quickly and accurately identifying patients suffering from potentially blinding eye diseases and preserving their vision. Using computer vision and image analysis expertise, the company is developing a portfolio of products based on its proprietary retinal image analysis technology combined with deep learning to identify and track the progression of eye diseases including diabetic retinopathy and age-related macular degeneration.
EyeArt™ has been cleared for sales as a Class IIa medical device by EU.
In the United States, EyeArt™ is limited by federal law to investigational use only and is not available for sale.
5850 Canoga Ave Suite 250, Woodland Hills, CA 91367, USA
+(1) 818 835 3585
# 696 Words